{"created":"2023-05-15T16:42:06.803159+00:00","id":16993,"links":{},"metadata":{"_buckets":{"deposit":"5db2c46f-0d43-49d8-9e74-a58f14921bbf"},"_deposit":{"created_by":2,"id":"16993","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"16993"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00016993","sets":["29:30"]},"author_link":["65962"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2000-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"2145","bibliographicPageStart":"2138","bibliographicVolumeNumber":"89","bibliographic_titles":[{"bibliographic_title":"日本内科学会雑誌"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"メトトレキサートはRAに対して他の抗リウマチ薬と比較して速やかに効果が発現し,有効性も優れており,長期間に亘り投与を継続できることが特徴である. これらの理由から,炎症が激しく,関節破壊が進行することが予想される症例では第一選択薬として積極的に使用される薬剤である.また,本剤は抗リウマチ薬 同士の併用療法においても中核となって用いられている.しかし,本剤の副作用の頻度は少なくなく,時に重篤な副作用を来たすことがあるため,使用にあたっ て副作用の予防,早期発見,早期対策が肝要である.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"日本内科学会雑誌, 89(10), pp.2138-2145; 2000","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本内科学会"}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright (c) 2000 (社)日本内科学会"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00195836","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00215384","subitem_source_identifier_type":"ISSN"}]},"item_2_text_62":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"The Japanese Society of Internal Medicine"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"江口, 勝美"}],"nameIdentifiers":[{"nameIdentifier":"65962","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"89_2138.pdf","filesize":[{"value":"686.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"89_2138.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/16993/files/89_2138.pdf"},"version_id":"8e675211-1a69-4654-8500-4f740b60fd35"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"抗リウマチ薬","subitem_subject_scheme":"Other"},{"subitem_subject":"メトトレキサート","subitem_subject_scheme":"Other"},{"subitem_subject":"慢性関節リウマチ","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫抑制薬","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"新しい治療法の考え方 抗リウマチ薬:メトトレキサートを中心に","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"新しい治療法の考え方 抗リウマチ薬:メトトレキサートを中心に"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-02-04"},"publish_date":"2010-02-04","publish_status":"0","recid":"16993","relation_version_is_last":true,"title":["新しい治療法の考え方 抗リウマチ薬:メトトレキサートを中心に"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-17T20:29:39.225783+00:00"}